STAA STAAR SURGICAL CO
Ophthalmic Goods · Nasdaq · SEC CIK 718937 · Fiscal year ends 01/02
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.4%
TTM net income YoY100.5%
TTM EPS YoY100.5%
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR-69.9%
Margins
Gross margin73.6%
Operating margin0.2%
Net margin0.2%
FCF margin5.4%
EBITDA margin2.9%
Returns
ROE0.1%
ROA0.1%
ROIC (approx.)0.2%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets22.5%
Debt / equity0.00x
Current ratio4.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income40.37x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-01-02 | FY20242024-12-27 |
|---|---|---|
| Income statement | ||
| Revenue | $239.44M | $313.90M |
| Cost of revenue | $57.02M | $74.32M |
| Gross profit | $182.42M | $239.58M |
| R&D expense | $40.05M | $45.32M |
| SG&A expense | $274.13M | $252.19M |
| Operating income | -$91.71M | -$12.61M |
| Pretax income | -$82.26M | -$9.05M |
| Income tax | -$1.81M | $11.16M |
| Net income | -$80.45M | -$20.21M |
| EBITDA | -$83.39M | -$5.72M |
| EPS (basic) | -1.62 | -0.41 |
| EPS (diluted) | -1.62 | -0.41 |
| Weighted avg. shares (diluted) | 49.57M | 49.12M |
| Balance sheet | ||
| Cash & equivalents | $153.15M | $144.16M |
| Short-term investments | $34.39M | $86.33M |
| Receivables | $50.06M | $77.90M |
| Inventory | $58.42M | $44.58M |
| Current assets | $311.55M | $367.94M |
| PP&E, net | $73.32M | $84.89M |
| Goodwill | $1.79M | $1.79M |
| Total assets | $451.68M | $509.52M |
| Current liabilities | $68.50M | $70.31M |
| Total liabilities | $107.49M | $112.19M |
| Shareholders' equity | $344.18M | $397.33M |
| Shares outstanding | 49.40M | 49.29M |
| Cash flow statement | ||
| Operating cash flow | -$34.23M | $15.72M |
| Capital expenditure | $5.82M | $23.39M |
| Free cash flow | -$40.05M | -$7.67M |
| Investing cash flow | $46.34M | -$59.22M |
| Financing cash flow | -$4.55M | $5.72M |
| Depreciation & amortization | $8.32M | $6.89M |
| Stock-based compensation | $30.59M | $27.21M |
| Share buybacks | $6.46M | — |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.